Foghorn Therapeutics (FHTX) Receivables - Net (2021)
Foghorn Therapeutics (FHTX) posted quarterly Receivables - Net of $300.0 million for Q4 2021.
Analysis
Foghorn Therapeutics (FHTX) Receivables - Net (2021) Analysis & Trends
Foghorn Therapeutics' Receivables - Net history runs 1 years deep, the most recent figure standing at $300.0 million for Q4 2021.
- In Q4 2021, Receivables - Net changed N/A year-over-year to $300.0 million; the TTM figure through Dec 2021 stood at $300.0 million (changed N/A YoY), while the FY2021 annual figure was $300.0 million, changed N/A from the prior year.
- Receivables - Net for Q4 2021 stood at $300.0 million.
- The five-year high for Receivables - Net was $300.0 million in Q4 2021, with the low at $300.0 million in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn |
| 10 | Foghorn Therapeutics | 346.79 Mn | 278.71 Mn | - |